BackBright Minds Biosciences Overview

Bright Minds Biosciences Total Liabilities

Track Bright Minds Biosciences's total liabilities ($3.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$3.83M
426.96% YoYΔ $3.10M vs prior year quarter

Peer average / median

Loading

Bright Minds Biosciences Total Liabilities History

Loading

Bright Minds Biosciences vs. peers: Total Liabilities Comparison

Loading

Bright Minds Biosciences Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bright Minds Biosciences (DRUG) FAQ

Bright Minds Biosciences (DRUG) currently reports a total liabilities of $3.8M as of March 2026. That compares with $730K in the prior-year period — up 427.0% year over year. Use the charts on this page to explore Bright Minds Biosciences's total liabilities history and peer comparisons.

Bright Minds Biosciences's total liabilities increased from $730K to $3.8M — a 427.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bright Minds Biosciences reported $3.8M in total liabilities as of March 2026. That compares with $730K in the prior-year period — up 427.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $3.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bright Minds Biosciences, and consider following DRUG for alerts when major investors trade the stock.

Bright Minds Biosciences is classified in the Healthcare sector. On total liabilities, it currently shows $3.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DRUG with unrelated industries.